In this Ardena Insight, we address the challenge of poor aqueous solubility in early-phase drug candidates and the formulation strategies designed to overcome it. As most compounds emerging from modern pipelines show limited solubility, enhancing absorption after oral administration becomes a critical goal.
While a variety of technologies exist to improve solubility and dissolution, no universal solution applies. Formulation choices must align with the drug’s physicochemical properties, permeability and dose. In early development, priority is given to approaches that support high drug loading, simple manufacturing, and flexible administration.
Ardena offers expert guidance to help you navigate formulation decisions for poorly soluble compounds, optimizing performance while accelerating development timelines.
